Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
Omics International publishes 304 Open Access Articles in 13 International Journals it has 32 Upcoming Conferences and 15 Previous Conferences with 581 Conference Proceedings and 92 National symposiums
Anxiety is a normal human emotion that everyone experiences at times. Many people feel anxious, or nervous, when faced with a problem at work, before taking a test, or making an important decision. Anxiety disorders, however, are different. They can cause such distress that it interferes with a person's ability to lead a normal life. There are several types of anxiety disorders including panic disorder, social anxiety disorder, specific phobias, and generalized anxiety disorder. The Omics Internationals promote the prevention, treatment, and cure of anxiety disorders and to improve the lives of all people who suffer through its conferences. A diverse array of scientists, clinicians, and consumers presented on a wide variety of topics at the conference.
OMICS International through its Open access initiatives is committed to make genuine and reliable contributions to the scientific community by publishing research work and conference paper related to such disorders. It is known that OMICS Group hosts over 700 edge peer reviewed Open Access Journals and organizes over more than 1000 Global Events annually. Its publishing group journals have over 5 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 75000+ eminent personalities that ensure a quality and quick review process checker.
Scope: About 1.2% of the UK population experience panic disorders, rising to 1.7% for those experiencing it with or without agoraphobia. 18.1% of US adults suffer from Anxiety disorders. Post-Traumatic Stress Disorder (PTSD) affects 2.6% of men and 3.3% of women. Obsessive Compulsive Disorders (OCD) affect around 2–3% of the population. Generalised Anxiety Disorder affects between 2–5% of the population, yet accounts for as much as 30% of the mental health problems seen by GPs. 2.6% of the population experience depression and 4.7% have anxiety problems, as many as 9.7% suffer mixed depression and anxiety, making it the most prevalent mental health problem in the population as a whole. Women are 60% more likely than men experience an anxiety disorder over their life time. 36.9% are receiving treatment for severe anxiety disorders.Anxiety disorder is one of the most common anxiety disorders. Estimates of lifetime prevalence vary but have been as high as 12%, compared with estimates for other anxiety disorders of around 6% for generalised anxiety disorder, 5% for panic disorder, 7% for post-traumatic stress disorder (PTSD) and 2% for obsessive-compulsive disorder. There is a significant degree of comorbidity between social anxiety disorder and other psychiatric disorders. Social anxiety disorder often occurs alongside depression (19%), substance use disorder (17%), generalised anxiety disorder (5%), panic disorder (6%), and PTSD (3%). Social anxiety disorder is common in both men and women, but tends to have a higher prevalence in women. Black and minority Social anxiety disorder final scope 2 ethnic groups have a higher incidence of common mental health disorders but may be under represented in treatment services. People with social anxiety disorder may use alcohol or other drugs to try to reduce their anxiety and alleviate depression. This can lead to substance abuse. A significant proportion of service users attending mental health services for conditions including anxiety disorders, such as panic disorder or social anxiety disorder, attend as a result of alcohol or benzodiazepine misuse. Social anxiety disorder has an early median age of onset (13 years) and is the most persistent of the anxiety disorders. Despite the extent of suffering and impairment only about half of those with the disorder ever seek treatment, and those that do generally seek treatment only after 15–20 years of symptoms. Social anxiety disorder may have a great impact on a person’s functioning, disrupt normal life, interfere with their social relationships and quality of life, and impair performance at work or school.
Global anxiety disorders and depression treatment market is expected to witness remarkable growth over the coming seven years due to rising incidences of depression and anxiety disorders coupled with growing geriatric population base. In addition, factors such as introduction of efficient products with less side effects and increasing demand for antidepressants used in treatment of panic disorders, phobias and obsessive compulsive disorder are expected to result in increased growth of this market over the forecast period. The global anxiety disorders and depression treatment market is categorized on the basis of drugs and pipeline analysis. By drugs, the market is divided into beta blockers, TeCAs (Tetracyclic Antidepressants), SNRIs (Serotonin Norepinephrine Reuptake Inhibitors), and TCAs (Tricyclic Antidepressants), SSRI (Selective Serotonin Reuptake Inhibitors), MAOIs (Monoamine Oxidase Inhibitors), anticonvulsants, atypical antipsychotics and benzodiazepines. The SNRIs market segment is expected to witness fastest growth owing to higher efficiency rate in treatment of generalized anxiety disorders. By pipeline analysis, the market is divided into ALKS 5461, Brintellix and Brexpiprazole. Increasing clinical trials and anticipated commercialization of pipeline products are expected to propel the growth of antidepressants drugs market over the forecast period. Regionally, as of 2014, North America witnessed highest share owing to increasing incidence of depression, availability of multi brand formulations and favourable government policies. European region is expected to witness rapid growth due to growing geriatric population base and increased usage of antidepressants in this region. Rising disposable income, awareness about antidepressants and prevalence of anxiety disorders are expected to result in fastest market growth in Asia pacific region. Also, Latin America region is anticipated to register steady growth owing to revamped healthcare facilities in this region. The market players operating in global anxiety disorders and depression treatment market are Johnson & Johnson, Merck & Co., Sanofi Aventis, Eli Lilly & Co., AstraZeneca plc, Pfizer Inc., GlaxoSmithKline plc, Forest Laboratories Inc. and H. Lundbeck A/S. The companies are adopting competitive strategies such as new product development and modification of distribution channels to increase their market penetration. For example, Forest Laboratories launched a drug namely Vilazodone in June 2014, which provides high tolerability, efficiency and safety in treatment of GAD (Generalized Anxiety Disorder). Also, in 2013, Eli Lilly and Co. introduced Duloxetine, a SNRI for the treatment of depressive disorder, generalized anxiety disorder and post-traumatic stress disorder.Many different types of medications are used in the treatment of anxiety disorders, including traditional anti-anxiety drugs such as benzodiazepines, and newer options like antidepressants and beta-blockers. These medications can be very effective, but they shouldn’t be thought of as a cure. Anxiety medication can provide temporary relief, but it doesn’t treat the underlying cause of the anxiety disorder. Once you stop taking the drug, the anxiety symptoms often return in full force. It’s important to be aware of the risks of anxiety medication, too. Anxiety medication can cause a wide range of unpleasant and sometimes dangerous side effects.
Many medications for anxiety are also habit forming and physically addictive, making it difficult to stop taking them once you’ve started.
Anti-anxiety drugs (tranquilizers / benzodiazepines)
Anti-anxiety drugs, also known as tranquilizers, are medications that relieve anxiety by slowing down the central nervous system. Their relaxing and calming effects have made them very popular: anti-anxiety drugs are the most widely prescribed type of medication for anxiety. They are also prescribed as sleeping pills and muscle relaxants.
Benzodiazepines are the most common class of anti-anxiety drugs. They include:
Benzodiazepines are fast acting—typically bringing relief within thirty minutes to an hour. Because they work quickly, benzodiazepines are very effective when taken during a panic attack or another overwhelming anxiety episode. But despite their potent anti-anxiety effects, they have their drawbacks.
Side effects of anti-anxiety drugs
Anti-anxiety drugs like benzodiazepines work by reducing brain activity. While this temporarily relieves anxiety, it can also lead to unwanted side effects.
The higher the dose, the more pronounced these side effects typically become. However, some people feel sleepy, foggy, and uncoordinated even on low doses of benzodiazepines, which can cause problems with work, school, or everyday activities such as driving. Some even feel a medication hangover the next day.
Because benzodiazepines are metabolized slowly, the medication can build up in the body when used over longer periods of time. The result is over sedation. People who are over sedated may look like they’re drunk.
OMICS Group International is a combination of Open Access publications and worldwide international science conferences and events. It was established in the year 2007 with the aim of making the information on Sciences and technology ‘Open Access’. OMICS Group also organizes 300 International conferences annually across the globe, where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions. OMICS International organizes Science Congress, World Summits, and International science conferences in India, USA, Dubai, Australia and Europe. OMICS Group Journalsencourages original and well researched articles for publication. With the help of a strong 30, 000 experts as editorial board members and reviewers, OMICS Group journals uphold the standard review process. All the articles submitted for publication are subjected to a blind peer review. Upon incorporating the changes the articles are published online. Once approved for publication, these articles remain archived permanently in their respective repositories. OMICS Group Journals follow online tracking system where the authors can submit their articles online and track its status from time to time.
To create more awareness in the field of Epilepsy OMICS Group is conducting a conferenceduringSeptember21-22, 2015 at Baltimore, USA. The theme of the conference is based on “New Insights of Advanced Research and Treatment strategies in Epilepsy”. Epilepsy-2015 event will provide two days of robust discussions for the treatment of various types of Epilepsy and its effects in pregnant women, Infantile Seizures, Genetic causes, mutations and other novel diagnostic and therapeutic strategies of Epilepsy. It will also explore new ideas and concepts on a global scale.
This page will be updated regularly.
This page was last updated on March 31, 2020